News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Asahi Kasei Pharma (AHKSY.PK) And CoTherix, Inc. (CTRX) Conclude Licensing Agreement For Fasudil, Rho-kinase Inhibitor


7/6/2006 6:02:25 PM

Tokyo, July 4, 2006 (JCN) - Asahi Kasei Pharma and CoTherix have entered into a licensing agreement for oral and inhaled formulations of fasudil, a rho-kinase inhibitor developed by Asahi Kasei Pharma. Under the agreement announced June 29, Asahi Kasei Parma will license CoTherix of California to develop and sell fasudil in North America and Europe. CoTherix plans to introduce the agent for the treatments of angina (oral formulation) and pulmonary hypertension (both oral and inhaled formulations).

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES